Unique ID issued by UMIN | UMIN000042289 |
---|---|
Receipt number | R000048279 |
Scientific Title | Safety and efficacy study of lotion |
Date of disclosure of the study information | 2020/10/30 |
Last modified on | 2021/05/18 12:21:13 |
Safety and efficacy study of lotion
Safety and efficacy study of lotion
Safety and efficacy study of lotion
Safety and efficacy study of lotion
Japan |
Healthy female
Dermatology | Adult |
Others
NO
The objective of this study is to evaluate the safety and efficacy of the test material with plant extract by visual evaluation and bioinstrumentation when applying the test material and placebo on the left or right side of face respectively for 21 weeks.
Safety,Efficacy
Hydration level of stratum corneum(0Weeks,13Weeks, and 21Weeks)
The activities on 0Weeks,13Weeks, and 21Weeks visits are as follows:
Photographs of facial image: VISIA-Evolution (Spots, Brown spots, UV spots, Skintexture, Wrinkles, and Pores)
Visual Evaluations
Wrinkle Grade Evaluations
Photographs of skin image: ANTERA 3D(Spots)
Skin color: Chromameter CM-600d
Skin color index: Mexameter
Trans-epidermal water loss: Vapometer SWL5001JT
Skin Viscoelasticity:Cutometer MPA580
Replicas
Photographic Evaluations (Spots and Wrinkles)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Other |
Apply the test material on the left face and placebo on the right face respectively twice a day for 21 weeks.
Apply the test material on the right face and placebo on the left face respectively twice a day for 21 weeks.
40 | years-old | <= |
60 | years-old | > |
Female
(1) Japanese female aged from 40 to 59 years;
(2) Subject who is willing to participate in the study and can comply with study requirements;
(3) Subject who has any age spots on the left or right side of face;
(4) Subject who has "crow's feet" wrinkles of grade 3 to 6 at the corners of both eyes; and
(5) Subject who dehydrates face skin in winter.
(1) Subject who is pregnant or nursing, or is planning to become pregnant or nursing during the study;
(2)Subject who used any drug, quasi-drug, or supplements, within 1 month before the baseline visit, that will affect the site to be examined;
(3) Subject who has a skin disorder such as atopic dermatitis;
(4) Subject who will take any skin care medication that may affect the results of the study;
(5) Subject who experienced any cosmetic medication that may affect the results of the study;
(6) Subject who is currently taking hormone replacement therapy;
(7) Subject who is participating in any other clinical trials; and
(8) Subject who otherwise disqualified from participation in the study for any reason at the discretion of the study physician.
25
1st name | Kazumi |
Middle name | |
Last name | Nozawa |
Interface, Inc.
Not applicable
010-0001
2-8-1-7, Nakadori, Akita-shi, Akita, 010-0001, Japan
018-827-7155
kazumi.nozawa@interface-akita.com
1st name | Miyuki |
Middle name | |
Last name | Kodama |
Interface, Inc.
Not applicable
010-0001
2-8-1-7, Nakadori, Akita-shi, Akita, 010-0001, Japan
018-827-7155
mkodama@interface-akita.com
Interface, Inc.
Fuji Sangyo, Inc.
Profit organization
The ethical committee of Interface, Inc.
2-8-1-7, Nakadori, Akita-shi, Akita, 010-0001, Japan
018-827-7155
mkodama@interface-akita.com
NO
2020 | Year | 10 | Month | 30 | Day |
Unpublished
Completed
2020 | Year | 10 | Month | 16 | Day |
2020 | Year | 10 | Month | 26 | Day |
2020 | Year | 10 | Month | 30 | Day |
2021 | Year | 03 | Month | 31 | Day |
2020 | Year | 10 | Month | 30 | Day |
2021 | Year | 05 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048279